{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:07:44Z","timestamp":1795108064894,"version":"4.10.3"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>\n                    Herein, we wanted to explore the molecular landscape of mucosal melanoma from different sites and identify potential molecular targets for future therapy. Mucosal melanomas (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    \u2009=\u200940) from different sites (conjunctiva, sinonasal cavity, rectum, and vagina) were investigated. Targeted next-generation sequencing along with Nanostring gene expression profiling was performed. Genetically, conjunctival melanoma was characterized by\n                    <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                    -V600E (30%) and\n                    <jats:italic toggle=\"yes\">NF1<\/jats:italic>\n                    mutations (17%). Mucosal melanomas at nonsun-exposed sites harbored alterations in\n                    <jats:italic toggle=\"yes\">NRAS<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">KIT<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">NF1<\/jats:italic>\n                    , along with atypical\n                    <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                    mutations. When comparing the gene expression profile of conjunctival melanoma and nonsun-exposed mucosal melanoma, 41 genes were found to be significantly deregulated. Programmed death-ligand 1 (PD-L1) presented a significant sixfold upregulation in conjunctival melanoma compared to the other mucosal melanomas. While melanomas of the sinonasal cavity, vagina, and rectum are molecularly similar, conjunctival melanoma is characterized by a higher frequency of\n                    <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                    -V600E mutations and differential expression of several genes involved in the immune response.\n                  <\/jats:p>","DOI":"10.1097\/cmr.0000000000000686","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T18:01:58Z","timestamp":1596045718000},"page":"533-542","source":"Crossref","is-referenced-by-count":28,"title":["The molecular profile of mucosal melanoma"],"prefix":"10.1097","volume":"30","author":[{"given":"Lauge Hjorth","family":"Mikkelsen","sequence":"first","affiliation":[{"name":"Eye Pathology Section, Department of Pathology"},{"name":"Department of Ophthalmology, Rigshospitalet, Copenhagen University Hospital, Copenhagen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Maag","sequence":"additional","affiliation":[{"name":"BioXpedia, Aarhus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Klarskov","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens","family":"Kruh\u00f8ffer","sequence":"additional","affiliation":[{"name":"BioXpedia, Aarhus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Cathrine","family":"Larsen","sequence":"additional","affiliation":[{"name":"Eye Pathology Section, Department of Pathology"},{"name":"Department of Ophthalmology, Rigshospitalet, Copenhagen University Hospital, Copenhagen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linea Cecilie","family":"Melchior","sequence":"additional","affiliation":[{"name":"Molecular Pathology Laboratory, Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Bjerre","family":"Toft","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Rigshospitalet, Copenhagen University Hospital, Copenhagen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"von Buchwald","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Wadt","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Heegaard","sequence":"additional","affiliation":[{"name":"Eye Pathology Section, Department of Pathology"},{"name":"Department of Ophthalmology, Rigshospitalet, Copenhagen University Hospital, Copenhagen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/apm.12529","article-title":"Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey.","volume":"124","author":"Mikkelsen","year":"2016","journal-title":"APMIS"},{"key":"R3-20230902","first-page":"3399","article-title":"Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites.","volume":"43","author":"Tuomaala","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/bjo.2009.157933","article-title":"Time trends in the incidence of conjunctival melanoma in Sweden.","volume":"93","author":"Triay","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/aos.13007","article-title":"BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions.","volume":"94","author":"Larsen","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3109\/0284186X.2016.1143117","article-title":"Primary mucosal melanoma of the head and neck in Denmark, 1982-2012: demographic and clinical aspects. A retrospective DAHANCA study.","volume":"55","author":"Lawaetz","year":"2016","journal-title":"Acta Oncol"},{"key":"R7-20230902","first-page":"22","article-title":"Primary sinonasal malignant melanoma: a nationwide study of the Swedish population, 1960-2000.","volume":"51","author":"Jangard","year":"2013","journal-title":"Rhinology"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.","volume":"10","author":"Newell","year":"2019","journal-title":"Nat Commun"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.5213","article-title":"Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities.","volume":"247","author":"Rabbie","year":"2019","journal-title":"J Pathol"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1158\/0008-5472.CAN-15-0262","article-title":"Evaluating robustness and sensitivity of the nanostring technologies ncounter platform to enable multiplexed gene expression analysis of clinical samples.","volume":"75","author":"Veldman-Jones","year":"2015","journal-title":"Cancer Res"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/cncy.20147","article-title":"Biospecimen reporting for improved study quality (BRISQ).","volume":"119","author":"Moore","year":"2011","journal-title":"Cancer Cytopathol"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK).","volume":"97","author":"McShane","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CLEP.S9908","article-title":"Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank.","volume":"2","author":"Erichsen","year":"2010","journal-title":"Clin Epidemiol"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamaophthalmol.2015.3200","article-title":"A Retrospective review of conjunctival melanoma presentation, treatment, and outcome and an investigation of features associated with BRAF mutations.","volume":"133","author":"Larsen","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/apm.12883","article-title":"Primary and secondary mucosal melanoma of the small intestine - a clinical, pathological, and genetic nationwide survey of Danish patients between 1980 and 2014.","volume":"126","author":"Tingsgaard","year":"2018","journal-title":"APMIS"},{"key":"R16-20230902","article-title":"AJCC Cancer Staging Manual 8th ed. American Joint Commission on Cancer: Springer International Publishing 2017.","author":"Amin"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.3892\/ol.2017.6713","article-title":"Genomic and immunohistochemical characterisation of a lacrimal gland oncocytoma and review of literature.","volume":"14","author":"Mikkelsen","year":"2017","journal-title":"Oncol Lett"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"75","DOI":"10.21037\/atm.2017.02.05","article-title":"Hierarchical cluster analysis in clinical research with heterogeneous study population: highlighting its visualization with R.","volume":"5","author":"Zhang","year":"2017","journal-title":"Ann Transl Med"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/cc1820","article-title":"Statistics review 6: nonparametric methods.","volume":"6","author":"Whitley","year":"2002","journal-title":"Crit Care"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B (Methodol)"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-0381-4-10","article-title":"Using graph theory to analyze biological networks.","volume":"4","author":"Pavlopoulos","year":"2011","journal-title":"Biodata Min"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apm.12901","article-title":"An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome.","volume":"127","author":"Andreasen","year":"2019","journal-title":"APMIS"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/bjc.2013.373","article-title":"KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.","volume":"109","author":"Zebary","year":"2013","journal-title":"Br J Cancer"},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41416-018-0046-5","article-title":"NF1 mutations in conjunctival melanoma.","volume":"118","author":"Scholz","year":"2018","journal-title":"Br J Cancer"},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/PAS.0000000000001166","article-title":"SF3B1, NRAS, KIT, and BRAF mutation; CD117 and cMYC expression; and tumoral pigmentation in sinonasal melanomas: an analysis with newly found molecular alterations and some population-based molecular differences.","volume":"43","author":"Wroblewska","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pathol.2016.09.065","article-title":"BRAF, NRAS, KIT, TERT, GNAQ\/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.","volume":"49","author":"Ozturk Sari","year":"2017","journal-title":"Pathology"},{"key":"R27-20230902","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CMR.0000000000000345","article-title":"Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.","volume":"27","author":"Hintzsche","year":"2017","journal-title":"Melanoma Res"},{"key":"R28-20230902","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/path.2289","article-title":"Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumor (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma.","volume":"214","author":"Pan","year":"2008","journal-title":"J Pathol"},{"key":"R29-20230902","doi-asserted-by":"crossref","first-page":"e24919","DOI":"10.1371\/journal.pone.0024919","article-title":"Angiomyolipoma have common mutations in TSC2 but no other common genetic events.","volume":"6","author":"Qin","year":"2011","journal-title":"PLoS One"},{"key":"R30-20230902","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/path.4996","article-title":"Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle\/desmoplastic melanomas.","volume":"244","author":"Jour","year":"2018","journal-title":"J Pathol"},{"key":"R31-20230902","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR.","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R32-20230902","doi-asserted-by":"crossref","first-page":"35753","DOI":"10.18632\/oncotarget.7099","article-title":"Dual mTORC1\/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.","volume":"7","author":"Varin","year":"2016","journal-title":"Oncotarget"},{"key":"R33-20230902","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/pcmr.12512","article-title":"Synergistic targeted inhibition of MEK and dual PI3K\/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.","volume":"29","author":"Wei","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"R34-20230902","first-page":"5874","article-title":"Combined mTOR\/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors.","volume":"23","author":"Li","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R35-20230902","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3390\/cancers11070930","article-title":"Combined treatment with MEK and mTOR inhibitors is effective in in vitro and in vivo models of hepatocellular carcinoma.","volume":"11","author":"Liu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R36-20230902","doi-asserted-by":"crossref","first-page":"24750","DOI":"10.18632\/oncotarget.25345","article-title":"Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma.","volume":"9","author":"Chadwick","year":"2018","journal-title":"Oncotarget"},{"key":"R37-20230902","doi-asserted-by":"crossref","first-page":"58021","DOI":"10.18632\/oncotarget.10770","article-title":"Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"key":"R38-20230902","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/cncr.30473","article-title":"Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.","volume":"123","author":"Hou","year":"2017","journal-title":"Cancer"},{"key":"R39-20230902","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"R40-20230902","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R41-20230902","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","article-title":"Melanoma subtypes demonstrate distinct PD-L1 expression profiles.","volume":"97","author":"Kaunitz","year":"2017","journal-title":"Lab Invest"},{"key":"R42-20230902","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-017-0627-0","article-title":"Immunotherapy in breast cancer: the emerging role of PD-1 and PD-L1.","volume":"19","author":"Bertucci","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"R43-20230902","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2217\/imt-2018-0110","article-title":"Programmed cell death-1\/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action.","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"key":"R44-20230902","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamaophthalmol.2018.3488","article-title":"Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma.","volume":"136","author":"Sagiv","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R45-20230902","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40425-019-0555-7","article-title":"Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.","volume":"7","author":"Finger","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R46-20230902","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"R47-20230902","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"R48-20230902","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis.","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J Clin Oncol"},{"key":"R49-20230902","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-07-741025","article-title":"The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy.","volume":"131","author":"Buchan","year":"2018","journal-title":"Blood"},{"key":"R50-20230902","doi-asserted-by":"crossref","first-page":"e000497","DOI":"10.1136\/esmoopen-2019-000497","article-title":"New emerging targets in cancer immunotherapy: the role of TIM3.","volume":"4","author":"Friedlaender","year":"2019","journal-title":"ESMO Open"},{"key":"R51-20230902","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41591-018-0265-6","article-title":"Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.","volume":"25","author":"Trucco","year":"2019","journal-title":"Nat Med"},{"key":"R52-20230902","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.","volume":"364","author":"Mandal","year":"2019","journal-title":"Science"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T20:50:55Z","timestamp":1723323055000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000686","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,21]]}}}